vs
百利高（PRGO）与Sunrun Inc.（RUN）财务数据对比。点击上方公司名可切换其他公司
Sunrun Inc.的季度营收约是百利高的1.0倍（$1.2B vs $1.1B），Sunrun Inc.净利率更高（8.9% vs -127.8%，领先136.7%），Sunrun Inc.同比增速更快（123.5% vs -2.5%），过去两年Sunrun Inc.的营收复合增速更高（59.0% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
Sunrun Inc.是美国知名的光伏系统及电池储能产品供应商，业务以服务住宅客户为主，2007年成立，总部位于加利福尼亚州旧金山，致力于为家庭用户提供高效的清洁能源解决方案。
PRGO vs RUN — 直观对比
营收规模更大
RUN
是对方的1.0倍
$1.1B
营收增速更快
RUN
高出126.0%
-2.5%
净利率更高
RUN
高出136.7%
-127.8%
两年增速更快
RUN
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.2B |
| 净利润 | $-1.4B | $103.6M |
| 毛利率 | 32.6% | — |
| 营业利润率 | -116.0% | 8.4% |
| 净利率 | -127.8% | 8.9% |
| 营收同比 | -2.5% | 123.5% |
| 净利润同比 | -3093.9% | 103.7% |
| 每股收益（稀释后） | $-10.23 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORUN
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.0B | $724.6M | ||
| Q2 25 | $1.1B | $569.3M | ||
| Q1 25 | $1.0B | $504.3M | ||
| Q4 24 | $1.1B | $518.5M | ||
| Q3 24 | $1.1B | $537.2M | ||
| Q2 24 | $1.1B | $523.9M | ||
| Q1 24 | $1.1B | $458.2M |
净利润PRGORUN
| Q4 25 | $-1.4B | $103.6M | ||
| Q3 25 | $7.5M | $16.6M | ||
| Q2 25 | $-8.4M | $279.8M | ||
| Q1 25 | $-6.4M | $50.0M | ||
| Q4 24 | $-44.4M | $-2.8B | ||
| Q3 24 | $-21.0M | $-83.8M | ||
| Q2 24 | $-108.4M | $139.1M | ||
| Q1 24 | $2.0M | $-87.8M |
毛利率PRGORUN
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — | ||
| Q1 24 | 33.1% | — |
营业利润率PRGORUN
| Q4 25 | -116.0% | 8.4% | ||
| Q3 25 | 7.0% | 0.5% | ||
| Q2 25 | 4.3% | -19.7% | ||
| Q1 25 | 4.5% | -22.8% | ||
| Q4 24 | 10.0% | -628.0% | ||
| Q3 24 | 7.4% | -23.8% | ||
| Q2 24 | -2.5% | -24.4% | ||
| Q1 24 | -5.1% | -40.0% |
净利率PRGORUN
| Q4 25 | -127.8% | 8.9% | ||
| Q3 25 | 0.7% | 2.3% | ||
| Q2 25 | -0.8% | 49.1% | ||
| Q1 25 | -0.6% | 9.9% | ||
| Q4 24 | -3.9% | -542.7% | ||
| Q3 24 | -1.9% | -15.6% | ||
| Q2 24 | -10.2% | 26.5% | ||
| Q1 24 | 0.2% | -19.2% |
每股收益（稀释后）PRGORUN
| Q4 25 | $-10.23 | $0.38 | ||
| Q3 25 | $0.05 | $0.06 | ||
| Q2 25 | $-0.06 | $1.07 | ||
| Q1 25 | $-0.05 | $0.20 | ||
| Q4 24 | $-0.32 | $-12.59 | ||
| Q3 24 | $-0.15 | $-0.37 | ||
| Q2 24 | $-0.79 | $0.55 | ||
| Q1 24 | $0.01 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | $14.7B |
| 股东权益账面价值 | $2.9B | $3.1B |
| 总资产 | $8.5B | $22.6B |
| 负债/权益比越低杠杆越低 | — | 4.69× |
8季度趋势，按日历期对齐
现金及短期投资PRGORUN
| Q4 25 | — | — | ||
| Q3 25 | $432.1M | — | ||
| Q2 25 | $454.2M | — | ||
| Q1 25 | $409.9M | — | ||
| Q4 24 | $558.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $542.8M | — | ||
| Q1 24 | $658.5M | — |
总债务PRGORUN
| Q4 25 | — | $14.7B | ||
| Q3 25 | — | $14.6B | ||
| Q2 25 | — | $14.0B | ||
| Q1 25 | — | $13.6B | ||
| Q4 24 | — | $12.9B | ||
| Q3 24 | — | $12.5B | ||
| Q2 24 | — | $12.0B | ||
| Q1 24 | — | $11.1B |
股东权益PRGORUN
| Q4 25 | $2.9B | $3.1B | ||
| Q3 25 | $4.4B | $3.0B | ||
| Q2 25 | $4.5B | $2.9B | ||
| Q1 25 | $4.4B | $2.6B | ||
| Q4 24 | $4.3B | $2.6B | ||
| Q3 24 | $4.6B | $5.3B | ||
| Q2 24 | $4.5B | $5.4B | ||
| Q1 24 | $4.7B | $5.2B |
总资产PRGORUN
| Q4 25 | $8.5B | $22.6B | ||
| Q3 25 | $10.1B | $22.2B | ||
| Q2 25 | $10.1B | $21.2B | ||
| Q1 25 | $9.8B | $20.4B | ||
| Q4 24 | $9.6B | $19.9B | ||
| Q3 24 | $11.2B | $22.1B | ||
| Q2 24 | $10.4B | $21.4B | ||
| Q1 24 | $10.6B | $20.8B |
负债/权益比PRGORUN
| Q4 25 | — | 4.69× | ||
| Q3 25 | — | 4.90× | ||
| Q2 25 | — | 4.80× | ||
| Q1 25 | — | 5.19× | ||
| Q4 24 | — | 5.05× | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 2.23× | ||
| Q1 24 | — | 2.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $96.9M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | — | 0.94× |
| 过去12个月自由现金流最近4个季度 | $145.1M | — |
8季度趋势，按日历期对齐
经营现金流PRGORUN
| Q4 25 | $175.4M | $96.9M | ||
| Q3 25 | $51.7M | $-121.5M | ||
| Q2 25 | $75.9M | $-292.7M | ||
| Q1 25 | $-64.5M | $-104.2M | ||
| Q4 24 | $312.6M | $-258.4M | ||
| Q3 24 | $42.2M | $-156.2M | ||
| Q2 24 | $9.5M | $-208.5M | ||
| Q1 24 | $-1.4M | $-143.1M |
自由现金流PRGORUN
| Q4 25 | $148.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | — | ||
| Q1 25 | $-90.0M | — | ||
| Q4 24 | $274.9M | — | ||
| Q3 24 | $15.1M | $-156.4M | ||
| Q2 24 | $-18.9M | — | ||
| Q1 24 | $-26.5M | — |
自由现金流率PRGORUN
| Q4 25 | 13.4% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 1.4% | -29.1% | ||
| Q2 24 | -1.8% | — | ||
| Q1 24 | -2.4% | — |
资本支出强度PRGORUN
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.5% | 0.0% | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.3% | — |
现金转化率PRGORUN
| Q4 25 | — | 0.94× | ||
| Q3 25 | 6.89× | -7.33× | ||
| Q2 25 | — | -1.05× | ||
| Q1 25 | — | -2.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.50× | ||
| Q1 24 | -0.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RUN
| Products | $692.3M | 60% |
| Customer Agreements | $435.2M | 38% |
| Manufactured Product Other | $56.7M | 5% |
| Incentives | $31.3M | 3% |
